https://orcid.org/0000-0002-5986-0190
References
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma [Internet]. Version 3.2022. Fort Washington (PA): National Comprehensive Cancer Network; June 2022 [cited 2022 Jun 08]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/cll.pdf.
- Estupiñán HY, Berglöf A, Zain R, et al. Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects. Front Cell Dev Biol. 2021;9:630942.
- McMullen JR, Boey EJ, Ooi JY, et al. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood. 2014;124(25):3829–3830.
- Byrd JC, Hillmen P, Ghia P, et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol. 2021;39(31):3441–3452.
- Common Terminology Criteria for Adverse Events (CTCAE). CTCAE v 5.0 [Internet]. U.S. Department of Health and Human Services; 2017 November [cited 2021 Aug 29]. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm.
- Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692–694.
- Donnelly JP, Chen SC, Kauffman CA, et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for research and treatment of cancer and the mycoses study group education and research consortium. Clin Infect Dis. 2020;71(6):1367–1376.
- Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020;395(10232):1278–1291.
- Ghia P, Pluta A, Wach M, et al. ASCEND: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2020;38(25):2849–2861.
- Munir T, Pitchford A, Bloor A, et al. Sudden or cardiac deaths on ibrutinib based therapy were associated with a prior history of hypertension or cardiac disease and the use of ACE-Inhibitors at study entry: analysis from the phase III NCRI FLAIR trial. Blood. 2021;138(Supplement 1):2636–2636.
- Bhat SA, Gambril JA, Azali L, et al. Ventricular arrhythmias and sudden death events following acalabrutinib initiation. Blood. 2022;140(20):2142–2145.
- Frei M, Aitken SL, Jain N, et al. Incidence and characterization of fungal infections in chronic lymphocytic leukemia patients receiving ibrutinib. Leuk Lymphoma. 2020;61(10):2488–2491.
- Furman RR, Byrd JC, Owen RG, et al. Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies. Leukemia. 2021;35(11):3201–3211.